TIL therapy is successfully treating some Siteman Cancer Center patients with metastatic melanoma

Siteman Cancer Center, based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, is one of the first centers nationwide to offer a newly approved cell-based immunotherapy that targets melanoma.
Tumor-infiltrating lymphocyte (TIL) therapy is now offered for certain patients with metastatic melanoma under the FDA's Accelerated Approval regulations.
“These types of cell-based immunotherapies have been very impactful in blood cancers,” said George Ansstas, MD, an associate professor of medicine at Washington University and leader of the solid tumor TIL program at Siteman. “We have seen progress in developing effective cell-based immunotherapies, and this is the first to be FDA-approved. While metastatic melanoma treatment was revolutionized with immune checkpoint therapy - the first immunotherapy for cancer - and many of our patients do very well, at some point most patients have some kind of recurrence. Now, we have another option to offer.”
Subscribe now ➤ bit.ly/2NNQiyM
For more great content from HEC Media check us out at:
Facebook ➤ bit.ly/1WPZEek
Twitter ➤ bit.ly/22qZDNU
Instagram ➤ bit.ly/1THSOnM